Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Popik

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Pharmacology, Biochemistry, and Behavior|April 26, 2020
R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder<sup>1</sup>J M Witkin, J Kranzler, K Kaniecki, et al.
Amino Acids|January 1, 1999
GlycineB antagonists as potential therapeutic agents. Previous hopes and present realityW Danysz, C G Parsons, M Karcz-Kubicha, et al.
Journal of Medicinal Chemistry|April 4, 1998
Molecular features associated with polyamine modulation of NMDA receptorsA H Lewin, G Sun, L Fudala, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
NMDA antagonist properties of the putative antiaddictive drug, ibogaineP Popik, R T Layer, L H Fossom, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 18, 2005
Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and miceT Kos, P Popik, M Pietraszek, et al.
Klinichna Khirurhiia|November 13, 2003
[Assessment of risk of thromboembolism in patients undergoing surgery]V F Saenko, A P Mazur, V V Grubnik, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Pharmacology, Biochemistry, and Behavior|April 26, 2020
R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder<sup>1</sup>J M Witkin, J Kranzler, K Kaniecki, et al.
Amino Acids|January 1, 1999
GlycineB antagonists as potential therapeutic agents. Previous hopes and present realityW Danysz, C G Parsons, M Karcz-Kubicha, et al.
Journal of Medicinal Chemistry|April 4, 1998
Molecular features associated with polyamine modulation of NMDA receptorsA H Lewin, G Sun, L Fudala, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
NMDA antagonist properties of the putative antiaddictive drug, ibogaineP Popik, R T Layer, L H Fossom, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 18, 2005
Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and miceT Kos, P Popik, M Pietraszek, et al.
Klinichna Khirurhiia|November 13, 2003
[Assessment of risk of thromboembolism in patients undergoing surgery]V F Saenko, A P Mazur, V V Grubnik, et al.
Pageof 7